Option chain shows key data for Bright Minds Biosciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bright Minds Biosciences.

Bright Minds Biosciences (NASDAQ:DRUG) Stock, Option Chain

Bright Minds Biosciences

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

BCTX

DRUG

RXRX


Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to keep their doors open during a pre-revenue period while they develop drug treatments and

Biotechs on the Brink: 2 Stocks With Huge Potential

Analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ELVA

EXOD

This Prudential Financial Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday

Exclusives

AAPL

AMZN

GLMD

GNPX

INTC

LUNR

MSFT

MSTR

NVDA

OKLO

PLTR

SMCI

SOFI

TSLA

TVGN

WHLR

WULF

A look at the most-searched tickers on Benzinga Pro for the month of October. Donald Trump and biotech stocks joined the top 10.

EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences Inc

DRUG FREE SOLUTION INC by Drug Free Solution Inc.

Drug Free Solution Inc

Drugs Made In America Acquisition Corp. - Ordinary Shares

Drugs Made In America Acquisition Corp

Drugs Made In America Acquisition Corp. - Units

Drugs Made In America Acquisition Corp. - Rights

Health Care

Press Releases

General

Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models

Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF

Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement

Peraso Inc. (NASDAQ: PRSO): Revolutionizing Military Combat with Steerable Beam Technology see more stocks inside…

Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data

Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement

Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting

Management

Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences Expands Scientific Advisory Board to Include Renowned Leaders in Epilepsy Research

Comments

Bright Minds Biosciences

Bright Minds Biosciences (DRUG) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga